Obviously, our findings provided an insight in elucidating the underlying mechanisms of NAFLD development and the CD38 may be a possible target for preventing liver steatosis and NAFLD. This evidence concerns the gene CD38 and metabolic dysfunction-associated steatotic liver disease.